Answer
Soliris (eculizumab) treats paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome in adults/children, refractory generalized myasthenia gravis in anti-AChR-positive patients ≥6 years, and relapsing neuromyelitis optica spectrum disorder in anti-AQP4-positive adults; PNH benefit is demonstrated with symptomatic high-activity haemolysis regardless of transfusion history.
Sources for this answer
- Soliris 300 mg concentrate for solution for infusionAlexion Pharma UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 29Document updated
Sources checked